Oarsman Capital Decreased Pfizer (PFE) Position, Dominion Midstream Partners Has 1.42 Sentiment

July 17, 2017 - By Vivian Park

Oarsman Capital Inc decreased Pfizer Inc. (PFE) stake by 48.86% reported in 2016Q4 SEC filing. Oarsman Capital Inc sold 22,795 shares as Pfizer Inc. (PFE)’s stock declined 3.45%. The Oarsman Capital Inc holds 23,862 shares with $775,000 value, down from 46,657 last quarter. Pfizer Inc. now has $198.93B valuation. The stock declined 0.52% or $0.17 reaching $33.26 per share. About 5.50 million shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since July 17, 2016 and is downtrending. It has underperformed by 19.46% the S&P500.

Dominion Energy Midstream Partners, LP, formerly Dominion Midstream Partners, LP, is a limited partnership. The company has market cap of $2.84 billion. The Firm is formed to grow a portfolio of natural gas terminaling, processing, storage, transportation and related assets. It has a 27.19 P/E ratio. The Company’s divisions include Dominion Energy, which consists of gas transportation, liquefied natural gas import and storage, and Corporate and Other.

Analysts await Dominion Energy Midstream Partners LP (NYSE:DM) to report earnings on August, 2 before the open. They expect $0.35 earnings per share, up 25.00% or $0.07 from last year’s $0.28 per share. DM’s profit will be $35.00 million for 20.29 P/E if the $0.35 EPS becomes a reality. After $0.37 actual earnings per share reported by Dominion Energy Midstream Partners LP for the previous quarter, Wall Street now forecasts -5.41% negative EPS growth.

Nbw Capital Llc holds 2.36% of its portfolio in Dominion Energy Midstream Partners LP for 277,590 shares. A. D. Beadell Investment Counsel Inc. owns 82,925 shares or 2.1% of their US portfolio. Moreover, Chickasaw Capital Management Llc has 2.07% invested in the company for 3.40 million shares. The New York-based Spirit Of America Management Corp Ny has invested 1.79% in the stock. Cushing Asset Management Lp, a Texas-based fund reported 1.54 million shares.

Ratings analysis reveals 67% of Dominion Midstream’s analysts are positive. Out of 3 Wall Street analysts rating Dominion Midstream, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $29.0 while the high is $30.0. The stock’s average target of $29.50 is 3.87% above today’s ($28.4) share price. DM was included in 3 notes of analysts from August 18, 2016. The firm has “Buy” rating given on Wednesday, September 14 by Stifel Nicolaus. The stock of Dominion Energy Midstream Partners LP (NYSE:DM) earned “Buy” rating by Mizuho on Friday, September 30. The stock has “Equal-Weight” rating by Morgan Stanley on Thursday, August 18.

About 39,051 shares traded. Dominion Energy Midstream Partners LP (DM) has risen 2.59% since July 17, 2016 and is uptrending. It has underperformed by 14.11% the S&P500.

Investors sentiment decreased to 1.13 in Q4 2016. Its down 0.05, from 1.18 in 2016Q3. It turned negative, as 60 investors sold PFE shares while 672 reduced holdings. 115 funds opened positions while 711 raised stakes. 4.12 billion shares or 1.11% more from 4.08 billion shares in 2016Q3 were reported. Private Advisor Grp Incorporated Ltd Liability Corp holds 0.44% or 410,330 shares. Td Asset Mgmt invested in 4.77 million shares or 0.26% of the stock. Jensen Invest Management owns 13,634 shares. Horan Cap Mngmt holds 2.39% or 284,039 shares in its portfolio. New Hampshire-based Wendell David Assocs has invested 0.3% in Pfizer Inc. (NYSE:PFE). Meridian owns 35,561 shares. 1.25M are owned by Mufg Americas Corporation. New England Private Wealth Ltd Liability stated it has 0.22% in Pfizer Inc. (NYSE:PFE). Dean Assoc Ltd Liability has 0.17% invested in Pfizer Inc. (NYSE:PFE). Folger Nolan Fleming Douglas Cap Inc invested in 0.23% or 38,264 shares. Barton Inv Mngmt stated it has 0.09% in Pfizer Inc. (NYSE:PFE). 54,608 were accumulated by Tiedemann Wealth Mgmt Ltd Limited Liability Company. Brookstone Cap Management owns 192,277 shares. Livforsakringsbolaget Skandia Omsesidigt reported 1.08% stake. Motco accumulated 110,129 shares or 0.4% of the stock.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on August, 1 before the open. They expect $0.65 earnings per share, up 1.56% or $0.01 from last year’s $0.64 per share. PFE’s profit will be $3.89 billion for 12.79 P/E if the $0.65 EPS becomes a reality. After $0.69 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -5.80% negative EPS growth.

Among 20 analysts covering Pfizer (NYSE:PFE), 7 have Buy rating, 1 Sell and 12 Hold. Therefore 35% are positive. Pfizer had 48 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Pfizer Inc. (NYSE:PFE) earned “Buy” rating by Jefferies on Monday, June 20. The company was maintained on Wednesday, October 28 by S&P Research. On Wednesday, November 25 the stock rating was upgraded by Suntrust Robinson to “Neutral”. Leerink Swann maintained Pfizer Inc. (NYSE:PFE) on Monday, May 2 with “Market Perform” rating. BMO Capital Markets maintained the stock with “Hold” rating in Monday, June 12 report. Societe Generale initiated Pfizer Inc. (NYSE:PFE) on Wednesday, April 6 with “Hold” rating. Jefferies maintained the shares of PFE in report on Thursday, July 13 with “Hold” rating. The rating was maintained by Credit Suisse on Monday, May 9 with “Outperform”. Cowen & Co upgraded Pfizer Inc. (NYSE:PFE) rating on Tuesday, October 20. Cowen & Co has “Outperform” rating and $43 target. The stock of Pfizer Inc. (NYSE:PFE) earned “Buy” rating by Jefferies on Tuesday, June 14.

Since February 27, 2017, it had 0 insider purchases, and 5 selling transactions for $5.16 million activity. LANKLER DOUGLAS M sold $693,200 worth of Pfizer Inc. (NYSE:PFE) on Thursday, March 2. Dolsten Mikael sold $2.02M worth of stock or 58,846 shares. JOHNSON RADY A sold 4,500 shares worth $153,855. 36,000 Pfizer Inc. (NYSE:PFE) shares with value of $1.23 million were sold by HILL CHARLES H.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.